1. A Pilot Study of Pro-Urokinase in the Treatment of Deep Vein Thrombosis
- Author
-
Paolo Prandoni, P. M. Mannucci, Marco Moia, Victor Gurewich, and M Pini
- Subjects
Adult ,Male ,Deep vein ,Hemorrhage ,Pilot Projects ,Fibrinogen ,Fibrin ,Fibrin Fibrinogen Degradation Products ,Fibrinolytic Agents ,medicine ,Humans ,Thrombolytic Agent ,Thrombolytic Therapy ,Aged ,alpha-2-Antiplasmin ,biology ,medicine.diagnostic_test ,Heparin ,business.industry ,Plasminogen ,Hematology ,Middle Aged ,Thrombophlebitis ,medicine.disease ,Urokinase-Type Plasminogen Activator ,Thrombosis ,Recombinant Proteins ,Treatment Outcome ,medicine.anatomical_structure ,Hemostasis ,Anesthesia ,biology.protein ,Drug Therapy, Combination ,Female ,Partial Thromboplastin Time ,business ,medicine.drug ,Partial thromboplastin time - Abstract
SummarySafety and efficacy of the thrombolytic agent pro-urokinase (pro-UK) in the treatment of deep vein thrombosis of the lower limbs (DVT) have been investigated in an open, uncontrolled, pilot study. Fifteen patients were infused with 800.000 IU (5 mg)/h of pro-UK over 24 h (120 mg), together with unfractionated heparin adjusted to maintain the activated partial thromboplastin time between 1.5 and 2.5 times the basal value. Efficacy was assessed comparing venographic changes in the 11 evaluable limbs before and after pro-UK infusion. The Marder score decreased from a median pre-thrombolysis value of 28 (range 4-40) to 16 (3-38) (p
- Published
- 1994